Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free REVBW Stock Alerts

Revelation Biosciences (REVBW) Competitors

Revelation Biosciences logo
$0.0098 0.00 (0.00%)
As of 07/31/2026
Compare

REVBW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Revelation Biosciences stock or one of its competitors? MarketBeat compares Revelation Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revelation Biosciences include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW).

How does Revelation Biosciences compare to Ainos?

Revelation Biosciences (NASDAQ:REVBW) and Ainos (NASDAQ:AIMDW) are related companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A N/A N/A
Ainos N/A N/A N/A

In the previous week, Revelation Biosciences had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for Ainos. Revelation Biosciences' average media sentiment score of 0.00 equaled Ainos'average media sentiment score.

Company Overall Sentiment
Revelation Biosciences Neutral
Ainos Neutral

Summary

Revelation Biosciences and Ainos tied by winning 1 of the 2 factors compared between the two stocks.

How does Revelation Biosciences compare to Alvotech?

Revelation Biosciences (NASDAQ:REVBW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

In the previous week, Revelation Biosciences and Revelation Biosciences both had 1 articles in the media. Alvotech's average media sentiment score of 0.67 beat Revelation Biosciences' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revelation Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alvotech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/AN/AN/AN/A
Alvotech$559.42MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats Revelation Biosciences on 2 of the 2 factors compared between the two stocks.

How does Revelation Biosciences compare to Aravive?

Aravive (NASDAQ:ARAV) and Revelation Biosciences (NASDAQ:REVBW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Revelation Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Revelation BiosciencesN/AN/AN/AN/AN/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Revelation Biosciences had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for Aravive. Aravive's average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company Overall Sentiment
Aravive Neutral
Revelation Biosciences Neutral

Summary

Aravive beats Revelation Biosciences on 2 of the 3 factors compared between the two stocks.

How does Revelation Biosciences compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Revelation Biosciences (NASDAQ:REVBW) are related companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Revelation Biosciences N/A N/A N/A

In the previous week, Revelation Biosciences had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Revelation Biosciences and 0 mentions for Atlantic Coastal Acquisition Corp. II. Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Revelation Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Revelation BiosciencesN/AN/AN/AN/AN/A

Summary

Revelation Biosciences beats Atlantic Coastal Acquisition Corp. II on 1 of the 1 factors compared between the two stocks.

How does Revelation Biosciences compare to Biofrontera?

Revelation Biosciences (NASDAQ:REVBW) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A N/A N/A
Biofrontera N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

In the previous week, Revelation Biosciences and Revelation Biosciences both had 1 articles in the media. Revelation Biosciences' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revelation Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biofrontera
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Biofrontera beats Revelation Biosciences on 1 of the 1 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for REVBW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REVBW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REVBW vs. The Competition

Export
MetricRevelation BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.75B$7.16B$12.47B
Dividend YieldN/A2.73%2.59%9.45%
P/E RatioN/A799.05282.2524.66
Price / SalesN/A742.69589.0589.75
Price / CashN/A73.1571.2359.99
Price / BookN/A10.9211.095.90
Net IncomeN/A$2.82B$3.50B$336.31M
7 Day PerformanceN/A-0.06%-0.24%0.09%
1 Month PerformanceN/A-3.91%-3.70%-5.17%
1 Year PerformanceN/A156.13%61.98%18.61%

Revelation Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REVBW
Revelation Biosciences
N/A$0.01
flat		N/AN/A$0.00N/AN/A10
AIMDW
Ainos
N/A$0.12
-4.7%		N/A-28.8%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.15
-19.0%		N/A-90.6%$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:REVBW) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners
One signature away. Expected within months.
On May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...
Behind the Markets | Sponsoredtc pixel
They’re still buying the wrong AI stocks
Tesla and Alphabet just tumbled, and many investors concluded AI is over. It isn't - the easy AI trade may be....
The Oxford Club | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
A New Gold Era Is Coming - Here's How to Help Protect Your Retirement Now
Washington insiders are quietly talking about a coordinated move to revalue gold—and with the national debt ap...
Preserve Gold | Sponsoredtc pixel
The dollar just broke
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel